Skip to main content

Day: January 5, 2022

O-I Glass Announces Full Year and Fourth Quarter 2021 Earnings Conference Call and Webcast

PERRYSBURG, Ohio, Jan. 05, 2022 (GLOBE NEWSWIRE) — FOR IMMEDIATE RELEASE O-I Glass, Inc. (NYSE: OI) has scheduled its full year and fourth quarter 2021 conference call and webcast for Wednesday, February 2, 2022, at 8 a.m. EST. The Company’s news release for the full year and fourth quarter 2021 earnings will be issued after the market closes on Tuesday, February 1. What:         O-I Conference Call and WebcastEarnings presentation materials will also be posted on the O-I website, www.o-i.com/investors, when the earnings news release is issued. When:         Wednesday, February 2, 2022, at 8 a.m. EST Where:         http://investors.o-i.com/webcasts-presentations?c=88324&p=irol-calendar The webcast will be archived at www.o-i.com/investors until February 2023. To participate in the event via conference call, dial 1-888-733-1701...

Continue reading

American Assets Trust, Inc. Increases Revolving Line of Credit to $400 Million and Extends Maturity Date in Its Third Amended and Restated Credit Agreement

SAN DIEGO, Jan. 05, 2022 (GLOBE NEWSWIRE) — American Assets Trust, Inc. (NYSE:AAT) (the “Company”) announced today that it has amended and restated its existing credit agreement. The credit agreement was amended and restated to, among other things, (1) increase the revolving line of credit from $350 million to $400 million, (2) extend the maturity date of the restated $400 million revolving line of credit to January 5, 2026 (with two, six-month extension options), (3) extend the maturity date of the $100 million term loan included as part of the credit agreement to January 5, 2027 (with no further extension options), (4) decrease the applicable ratings-based pricing spreads and (5) transition borrowings to the Secured Overnight Financing Rate (SOFR), and away from LIBOR. The revolving line of credit and $100 million term loan are...

Continue reading

Richardson Electronics Reports Second Quarter Fiscal 2022 Net Income Of $4.1 Million And Declares Quarterly Cash Dividend

PMT, Canvys and Healthcare Revenues Grow Versus Second Quarter FY21 Second Quarter HighlightsNet sales of $54.0 million were up 27.3% from last year’s second quarter. Sales increased for PMG, Canvys, Healthcare and Semiconductor Wafer Fabrication Equipment products in the second quarter of fiscal 2022 versus the second quarter of fiscal 2021. Backlog increased to $146.9 million in the second quarter versus $126.5 million at the end of the first quarter. Gross margin was 32.7% of net sales for the second quarter of fiscal 2022 versus 33.8% of net sales in the prior year’s second quarter primarily due to product mix and higher global freight costs. Operating expenses decreased $0.4 million to $13.1 million compared to the prior year’s second quarter. This decrease was due to lower legal fees, partially offset by increased employee compensation...

Continue reading

CTO Realty Growth Announces Record 2021 Transaction Activity

WINTER PARK, Fla., Jan. 05, 2022 (GLOBE NEWSWIRE) — CTO Realty Growth, Inc. (NYSE: CTO) (the “Company” or “CTO”) today announced its record 2021 acquisition and disposition activities. 2021 Acquisition HighlightsDuring the year ended December 31, 2021, the Company acquired eight mixed use or retail income properties for total acquisition volume of $249.1 million, representing a weighted-average going-in cash cap rate of 7.2%. The 2021 acquisitions are in well-located submarkets of the high-growth markets of Las Vegas, Nevada; Salt Lake City, Utah; Dallas, Texas; Raleigh, North Carolina; Santa Fe, New Mexico; Orlando, Florida; and Atlanta, Georgia. Notable new tenants in the Company’s portfolio include Sprouts, Burlington, At Home, TJ Maxx, HomeGoods, Synovus, Ross Dress for Less, Season’s 52, WeWork, Dick’s Sporting Goods and...

Continue reading

Saratoga Investment Corp. Announces Fiscal Third Quarter 2022 Financial Results

NEW YORK, Jan. 05, 2022 (GLOBE NEWSWIRE) — Saratoga Investment Corp. (NYSE:SAR) (“Saratoga Investment” or “the Company”), a business development company (“BDC”), today announced financial results for its 2022 fiscal third quarter. Summary Financial Information The Company’s summarized financial information is as follows:  For the quarterended and as ofNov 30, 2021 For the quarterended and as ofAug 31, 2021 For the quarterended and as ofNov 30, 2020  ($ in thousands except per share)AUM 661,793   666,097   546,944  NAV 324,602   324,112   299,853  NAV per share 29.17   28.97   26.84  Investment Income 16,502   18,442   14,283  Net Investment Income per share 0.45   0.57   0.40  Adjusted Net Investment Income per share 0.53   0.63   0.50  Earnings per share 0.73   0.71   0.57  Dividends per share (declared) 0.53   0.52   0.42  Return...

Continue reading

Landec Corporation Reports Second Quarter Fiscal Year 2022 Results

Reiterates Fiscal 2022 Guidance for Lifecore Provides Pro Forma Curation Foods Segment Results and Updates Guidance for Continuing Segment Operations SANTA MARIA, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) — Landec Corporation (Nasdaq: LNDC) (“Landec” or the “Company”), a diversified health and wellness company with two operating businesses, Lifecore Biomedical, Inc. (“Lifecore”) and Curation Foods, Inc., reported results for the fiscal 2022 second quarter ended November 28, 2021. Subsequent to fiscal second quarter end, on December 13, 2021 the Company closed on the sale of its Curation Food’s fresh packaged salads and vegetables business (the “Eat Smart Disposition”) for $73.5 million in cash, subject to certain adjustments. Looking forward, Landec continues to focus on creating shareholder value through strengthening...

Continue reading

Intellia Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022

CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics leveraging CRISPR-based technologies, today announced that the company is scheduled to present virtually at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 2:15 p.m. ET. A live audio webcast of Intellia’s presentation can be accessed under the Events and Presentations page of the Investors & Media section on the company’s website at www.intelliatx.com. A replay of the audio webcast will be available on Intellia’s website for at least two weeks following the presentation. About Intellia TherapeuticsIntellia Therapeutics, a leading clinical-stage genome editing company, is developing novel, potentially curative...

Continue reading

Context Therapeutics® Strengthens Research & Development Team

Company names Christopher Beck as SVP, Operations and Mark Fletcher, Ph.D., as VP, R&D PHILADELPHIA, Jan. 05, 2022 (GLOBE NEWSWIRE) — Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing small molecule and immunotherapy treatments for breast and gynecological cancers, today announced the appointments of Christopher Beck as SVP of Operations and Mark Fletcher, Ph.D., as VP of R&D. Context also announced the planned retirement of its current Head of CMC, Bill Rencher, Ph.D., who will move into an advisory role with the Company. “Context is in a pivotal phase of growth and change as we near key inflection points with our pipeline, bolstered by our recent private placement and initial public offering. As part of Context’s leadership, Mr. Beck and Dr. Fletcher will help...

Continue reading

NexImmune Announces Formation of Autoimmune and Infectious Diseases Scientific Advisory Board

GAITHERSBURG, Md., Jan. 05, 2022 (GLOBE NEWSWIRE) — NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced the formation of its Autoimmune and Infectious Disease Scientific Advisory Board (AI & ID SAB). The AI & ID SAB is comprised of distinguished academic and industry leaders in the fields of autoimmune and infectious diseases, translational research, immunology and T cell biology. “As we continue to advance our AIM nanotechnology platform, we are grateful to have the input and guidance of these established experts,” said Jerry Zeldis, NexImmune’s EVP of R&D. “Their combined experience in autoimmune and infectious diseases, translational...

Continue reading

CBTX, Inc. Announces Date of Fourth Quarter 2021 Financial Results Conference Call

HOUSTON, Jan. 05, 2022 (GLOBE NEWSWIRE) — CBTX, Inc., or the Company (NASDAQ: CBTX), the bank holding company for CommunityBank of Texas, N.A., or the Bank, today announced it will hold a quarterly conference call to discuss fourth quarter 2021 financial results on Friday, January 28, 2022 at 8:00 a.m. Central Time (9:00 a.m. Eastern Time). To access the live webcast of the conference call, individuals can visit the Investor Relations page of the Company’s website: https://ir.cbtxinc.com/events-and-presentations. An archived edition of the earnings webcast will also be posted on the Company’s website and will remain available to interested parties via the same link for one year. The conference call can also be accessed by dialing (877) 620-1733 if calling from the U.S. or Canada (or (470) 414-9785 if calling from outside the U.S.)....

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.